Reviews/Osteoporosis Fracture Prevention/Vitamin D alone fracture prevention
Calcium And Vitamin D · ostfrac_12 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across the trials gathered here, giving vitamin D on its own did not lower the chance of breaking a bone. A very large study of generally healthy older adults found fracture rates essentially the same whether people took vitamin D or a dummy pill [1], and three separate trials in nursing-home and care-home residents reached the same conclusion [2][3][4]. The result held across different doses, formulations and settings, which is why the panel treated the finding as consistent rather than a fluke. The main open edge is that none of these trials specifically enrolled people who were severely vitamin D deficient or who already had osteoporosis. So the evidence is strong for the general wording of the claim, while leaving those particular subgroups unresolved.
Four randomized trials testing vitamin D supplementation alone report no significant reduction in fracture risk. The largest, VITAL [1] (N=25,871), found a total-fracture hazard ratio of 0.98 (95% CI, 0.89 to 1.08) with null results also for nonvertebral and hip fractures. In frail nursing-home residents, 10 µg/day of vitamin D3 produced no difference in hip fracture (p = 0.66) despite raising serum 25-hydroxyvitamin D by 22 nmol/liter [2]. A cluster trial in British care homes found no evidence that vitamin D prevents fractures or falls [3], and a pragmatic institutional trial reported a hazard ratio of 0.95 (95% CI, 0.79-1.15), not statistically significant [4]. The signal is consistent across populations, doses and formulations. The contested point: The division is about reach rather than direction: every trial points to no effect, but [1] explicitly did not recruit on vitamin D deficiency, low bone mass, or osteoporosis, and [2][3][4] are confined to institutional or frail elderly. The question is whether a genuinely null result in these populations extends to overtly deficient or osteoporotic patients, who are not isolated anywhere in this corpus.
All 5 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Osteoporosis Fracture Prevention, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
VITAL [1] explicitly did not recruit on vitamin D deficiency, low bone mass or osteoporosis; the broad claim may not hold in frankly deficient populations, though [2] raised serum 25-OHD by 22 nmol/L and still saw no effect.
Three of four included trials ([2],[3],[4]) are in institutional/frail elderly, limiting generalizability; only [1] covers community-dwelling midlife/older adults.
Where it remains uncertain. None of the trials enrolled people selected for vitamin D deficiency, low bone mass, or osteoporosis [1], so a residual effect in those subgroups is not excluded by this corpus.
Aleatory
Some trials recorded low absolute fracture incidence (e.g. [3] reports 3.2% per year non-vertebral and 1.1% per year hip), so chance variation in event counts bears on precision.
Epistemic
No trial recruited on vitamin D deficiency, low bone mass, or osteoporosis [1], so the effect in frankly deficient people is not directly observed here.
The load-bearing papers from a corpus of 5, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Large, high-powered RCT in general midlife/older population shows null fracture effect of vitamin D alone across total, nonvertebral and hip endpoints.
“Supplemental vitamin D3, as compared with placebo, did not have a significant effect on total fractures (which occurred in 769 of 12,927 participants in the vitamin D group and in 782 of 12,944 participants in the placebo group; hazard ratio, 0.98; 95% confidence interval [CI], 0.89 to 1.08; P = 0.70)”
Panel auditInternal validity: high · scope of inference: Generally healthy midlife and older US adults not selected for vitamin D deficiency, low bone mass, or osteoporosis.Key limitations: participants not selected for deficiency or low bone mass · fractures self-reported on questionnaires then adjudicated · median follow-up only 5.3 years
Isolates vitamin D alone (vs calcium-combined regimens) and finds no fracture reduction despite confirmed rise in serum 25-OHD.
“we found that an intervention with 10 microg of vitamin D3 alone produced no fracture-preventing effect in a nursing home population of frail elderly people”
Panel auditInternal validity: medium · scope of inference: Frail elderly residents of nursing homes.Key limitations: low vitamin D dose (10 microg) · 2-year study period · small number of fracture events
Independent cluster RCT corroborating the null effect on both fractures and falls.
“We found no evidence that vitamin D prevents fractures or falls in elderly people in care home accommodation.”
Panel auditInternal validity: medium · scope of inference: Elderly people (average age 85, mostly women) in UK residential and nursing care homes.Key limitations: median follow-up only 10 months · high baseline 25-hydroxyvitamin D · low event rate limiting power · cluster-randomized design
3 of 5 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, precise null results across multiple well-conducted independent RCTs, including one very large trial, firmly support the claim as worded.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Deficiency-selected trial. Every included trial avoided selecting for deficiency; [1] confirms participants were not recruited on the basis of vitamin D deficiency, low bone mass, or osteoporosis, so the deficient subgroup is the clearest untested edge of the claim. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized trial of vitamin D alone restricted to participants with documented baseline vitamin D deficiency, with incident fracture as the primary endpoint.
Open question: Does vitamin D supplementation alone reduce fracture risk in people who are overtly vitamin D deficient at baseline? Why it is still open: No trial in the corpus recruited on deficiency; [1] excluded deficiency-based selection, and while [2] raised 25-hydroxyvitamin D by 22 nmol/liter without effect, it was not a deficiency-selected cohort.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19